Lung cancer screening with low-dose computed tomography for medicare beneficiaries
Ces deux articles, accompagnés d'un éditorial, présentent deux points de vue opposés concernant l'intérêt de la tomographie à faible dose de rayonnements pour détecter un cancer du poumon chez les personnes bénéficiant de l'assurance maladie Medicare (âge supérieur à 65 ans)
Lung cancer, the vast majority of cases of which are caused by smoking, is the leading cause of cancer deaths in both men and women in the United States. In 2014, about 160 000 people are expected to die from lung cancer, accounting for about 27% of all cancer deaths.
Although the prevention of deaths from lung cancer is a public health priority, the role of screening has been unclear. In 2011, the National Lung Screening Trial found that screening with low-dose computed tomography (CT) reduced mortality. In 2013, the US Preventive Services Task Force issued a B recommendation for screening with low-dose CT for high-risk current and former smokers, concluding that the screening was likely to offer moderate to substantial net benefit.
JAMA Internal Medicine , éditorial, 2013